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Background: Shigella flexneri is a gram negative bacteria that causes the infectious
disease “shigellosis.” S. flexneri is responsible for developing diarrhea, fever, and
stomach cramps in human. Antibiotics are mostly given to patients infected with shigella.
Resistance to antibiotics can hinder its treatment significantly. Upon identification of
essential therapeutic targets, vaccine and drug could be effective therapy for the
treatment of shigellosis.
Methods: The study was designed for the identification and qualitative characterization
for potential drug targets from S. flexneri by using the subtractive proteome analysis. A
set of computational tools were used to identify essential proteins those are required for
the survival of S. flexneri. Total proteome (13,503 proteins) of S. flexneri was retrieved
from NCBI and further analyzed by subtractive channel analysis. After identification of
the metabolic proteins we have also performed its qualitative characterization to pave
the way for the identification of promising drug targets.
Results: Subtractive analysis revealed that a list of 53 targets of S. flexneri were human
non-homologous essential metabolic proteins that might be used for potential drug
targets. We have also found that 11 drug targets are involved in unique pathway. Most
of these proteins are cytoplasmic, can be used as broad spectrum drug targets, can
interact with other proteins and show the druggable properties. The functionality and
drug binding site analysis suggest a promising effective way to design the new drugs
against S. flexneri.
Conclusion: Among the 53 therapeutic targets identified through this study, 13 were
found highly potential as drug targets based on their physicochemical properties whilst
only one was found as vaccine target against S. flexneri. The outcome might also be
used as module as well as circuit design in systems biology.
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Hossain et al. Therapeutic Targets for Shigella flexneri
INTRODUCTION
In developing countries, S. flexnari is the foremost reason of
bacillary dysentery among the four species of Shigella. Annually,
1.1 million deaths occur out of 164.7 million cases of Shigellosis
worldwide and children <5 years of age are the worst victim
of it (Bardhan et al., 2010). Depending on the combinations
of antigenic determinants existing on the O antigen of the cell
envelope lipopolysaccharide (LPS)(2–14), S. flexneri is divided
into 19 serotypes viz. serotypes 1a, 1b, 1c, 1d, 2a, 2b, 3a, 3b, 4a, 4av,
4b, 5a, 5b, X, Xv, Y, Yv, F6, and 7b (Simmons and Romanowska,
1987; Kotloff et al., 1999; Stagg et al., 2009; Ye et al., 2010; Foster
et al., 2011; Sun et al., 2011, 2012; Luo et al., 2012; Perepelov et al.,
2012).
Shigella, as Gram-negative facultative human pathogens,
cause intestinal infections with sign and symptoms such as
fever, abdominal cramps and watery, or bloody diarrhea. Recent
evidence suggests that the third prominent reason of global infant
mortality is diarrhea (Black et al., 2010). Children below the
age of five are mostly affected by Shigella (Kotloff et al., 1999;
Peng et al., 2002). Majority of endemic dysentery are caused
by S. flexneri in regions of the world having less facility of
sanitation. Also, improper use of antibiotic rendered resistance
to shigella. Therefore, antimicrobials development could be
the better alternatives for the prevention of antibiotic-resistant
Shigella as it is non-toxic, cheap, easy to apply and produce
life-long immunity (Kärnell et al., 1995; Coster et al., 1999;
Mukhopadhaya et al., 2003, 2006; Katz et al., 2004; Ranallo
et al., 2005; Paterson, 2006). Recently, it has been reported that
Shigella serotypes including S. flexneri 2a, 3a, S. dysenteriae 1,
and S. sonnei are targeted for vaccine development. In developing
countries, the first three are more widespread while the last
serotypes found in regions where sanitation standard is high
(Jennison and Verma, 2004; Mukhopadhaya et al., 2006).
Antibiotic is mostly given for the treatment with shigella
infection. But the high failure rate is increasing day by day
due to acquired resistance to commonly used antibiotics
(Nessar et al., 2012). To combat these infections new drugs
discovery are necessary due to emerging multi-drug resistance
and absence of optimal treatment. Therefore, to identify novel
drug target(s) are one of the key ways of drug discovery. The
present study is aimed to identify potential drug targets in S.
flexneri by subtractive proteome analysis. The traditional way
of drug discovery needs more times, expensive experiments
and also laborious efforts whereas the computational way could
be effective alternative way which could accelerate of drug
discovery process within a very short time. The identification
of drug targets has been growing more by coupling of “omics”
data viz., genomics, proteomics, and metabolomics and the
utilization of computational approaches. The sequencing
of genome and revealing of proteome of disease causing
organisms are advancing the search of drug targets in the field
of drug research based on essential genes of specific pathogen,
interacting factors of host-pathogen, proteins persistence,
resistance genes/resistance-associated proteins, metabolic
pathways, prediction of gene expression levels (Galperin and
Koonin, 1999; Yeh et al., 2004; Briken, 2008; Raman et al.,
2008; Barh et al., 2011; Vetrivel et al., 2011). To identify novel
drug targets these approaches have already been utilized in
several life threatening pathogens, including Mycobacterium
tuberculosis (Anishetty et al., 2005; Asif et al., 2009), M. leprae
(Shanmugam and Natarajan, 2010), M. ulcerans (Butt et al.,
2012), Helicobacter pylori (Sarkar et al., 2012), Streptococcus
pneumonia (Singh et al., 2007), Yersinia pestis (Sharma and Pan,
2012), and Pseudomonas aeruginosa (Sakharkar et al., 2004). The
foremost criteria for the identification of promising therapeutic
candidates are essentiality and selectivity/specificity. To avoid
the undesired interactions of host-pathogen which could occur
to death of the pathogen by mediating inhibition of important
proteins, the targets must be specific as drugs interact to host
proteins. The present study integrates the various computational
methods for the identification and characterization of the drug
targets of S. flexneri which enables us to identify 53 potential
therapeutic targets based on essentiality and specificity. The
qualitative characterization of 53 therapeutic candidates predicts
the uniqueness in metabolic pathway, capability to act as a
broad spectrum target, the cellular location, cellular function,
functional association with metabolic proteins, and druggability
properties.
MATERIALS AND METHODS
An in silico systematic method consists of three stages is applied
to classify and illustrate possible drug targets against S. flexneri.
At the stage I, the protein dataset was collected from the
NCBI–FTP site for the analysis. Clarification of protein datasets
through subtractive channel of analysis was done in stage II and
possible drug targets found from stage I and II were qualitatively
characterized in stage III.
Stage I: Mining of Protein Datasets
The whole protein sequences of S. flexneri 2a strain 2457T were
retrieved from NCBI (http://www.ncbi.nlm.nih.gov/) protein
database as FASTA format.
Stage II: Subtractive Channel of Analysis
Protein datasets were further selected and subjected to be
qualified by passing through a sequence of subtractive proteome
analysis. In this process, highly discerning and effective drug
targets could be identified.
Identification of Paralog Proteins
Paralog proteins were identified by exposing S. flexneri proteins
to CD-hit suite (Huang et al., 2010). The CDHIT server can
be utilized for the “sequence identity” among the proteins
(Fasta file). In this server users can exploit 10–90% sequence
identity in the “sequence identity cut-off” box depending on
their requirement (Huang et al., 2010). It has been widely
accepted to set 60% sequence identity as cut-off to maintain a
rigid criteria to remove duplicate proteins (Dutta et al., 2006;
Barh and Kumar, 2009; Rahman et al., 2014; Mondal et al.,
2015; Hasan et al., 2016). Therefore, we have used CDHIT
server (http://weizhong-lab.ucsd.edu/cdhit_suite/cgi-bin/index.
cgi?cmd=cd-hit) in which 0.6 (60%) was manually set in
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“sequence identity cut-off” box for the stringent selection of
duplicate proteins. The duplicates were omitted and for further
selection those were designated from the remaining set of non-
paralog proteins that have in excess of 100 amino acids.
Identification of Orthologs in Gut Flora
The non-duplicate proteins that were described in the preceding
step, analyzed to explore their similarity with the proteome
of human gut microbiota (Fujimura et al., 2010). BLASTing
(Altschul et al., 1990) of those proteins against the gut flora
proteome available from literature with 0.0001 as e-value
threshold helped to further escape from the orthologs.
Identification of Orthologs in Human Proteome
BLASTp (Altschul et al., 1990) was done for the qualified
proteins resulted from stage I against non-redundant database
of H. sapiens with an estimated threshold value of 0.0001. Those
proteins are selected for the next step that shows no hits for the
above mentioned e-value.
Essentiality Analysis
To identify essential proteins by BLASTp searching against
Database of Essential Genes (DEG; Zhang and Lin, 2009),
non-homologous proteins were screened. Protein alignments
associated with expect value of<0.0001(Barh et al., 2011; Sharma
and Pan, 2012) were considered as more significant hits.
Metabolic Pathway Analysis
Metabolic pathway analysis was done by KAAS server at KEGG
to classify the possible targets of the human non-homologous
essential proteins of S. flexneri which has been assimilated from
DEG (Moriya et al., 2007). Functional annotation of genes is
obtained through KAAS by comparing BLAST beside manually
created KEGG GENES database. The result comprises of KO
(KEGG Orthology) task that identify the metabolic proteins.
Stage III: Qualitative Characterization of
the Short-Listed Targets
Detection of Proteins Involved In Unique Pathways
KEGG (Kyoto Encyclopedia of Genes and Genomes) Genome
Database (Kanehisa et al., 2014) was applied to find the distinctive
metabolic pathways of S. flexneri in contrast to H. sapiens.
In order to compare the metabolic pathway three letter codes
that are particular for host and pathogen was placed in the
Genome Comparison and Combination box. Eventually KEGG
Genome generated pathway maps were recognized as distinctive
pathways. Human non-homologousmetabolic proteins that were
selected formerly were subjected to screening to disclose their
association in those distinctive pathways.
Cellular Localization Analysis
In this study, PSORTb 3.0.2(Yu et al., 2010), CELLO 2.0(Yu
et al., 2006), Signal IP 4.1(Petersen et al., 2011), and Phobius
(Käll et al., 2007) were used to identify the location of the short-
listed proteins in various modules like SVM, S-TMHMM, and
SCL-BLAST with proteins of known localization from bacteria
(Gram-positive and negative) and archaea as training set. These
server were used for the accurate localization of identified targets.
Broad Spectrum Analysis
BLASTp (Altschul et al., 1990) search was done beside a
wide-range of pathogenic bacteria to explore proteins with an
estimated threshold value of 0.005 to find broad spectrum targets.
In the broad spectrum analysis, overall 240 disease-causing
bacteria from different genus including with other serotypes of
S. flexneri were used. Cluster of Orthologous Groups of proteins
(COG) search was used to identify homologs of the short listed
targets in other pathogenic bacteria by means of COGnitor from
NCBI that matches the query sequence with the COG database.
Interactome Analysis
STRING 9.0 (Szklarczyk et al., 2011) was used to build a
protein-protein interaction network for each of the authorized
targets. All interactors with low along with medium confidence
score (<0.700) were removed from the network to escape false
positives and false negatives.
Functionality Analysis
INTERPROSCAN, a tool that incorporates various protein
signature recognitionmethods and databases, was used to predict
the role of the hypothetical proteins from the list of possible
targets (Mulder and Apweiler, 2007).
Binding Site Analysis
Local meta-threading-server (LOMETS; Wu and Zhang, 2007)
was used for the selection of best template from 9 locally-
installed threading programs (FFAS-3D, HHsearch, MUSTER,
pGenTHREADER, PPAS, PRC, PROSPECT2, SP3, and SPARKS-
X). Then, Modeller 9.17 (Webb and Sali, 2014) was used to build
the 3D model of metabolic hypothetical proteins. A set of tools
Procheck (Laskowski et al., 1993), Verify3D (Eisenberg et al.,
1997), and proSA (Wiederstein and Sippl, 2007) were utilized
for the model quality assessment. Thereafter, COFACTOR server
(Roy et al., 2012) was also employed to reveal out the binding site
of 6 metabolic hypothetical proteins.
Druggability Analysis
In the current study, a similarity search was done in contrast to
Drug Bank 3.0 target collection for all of the target (Knox et al.,
2011).
Docking Analysis
We have performed Autodock vina (Trott and Olson, 2010)
for the analysis of binding affinity to the druggable targets. We
retrieved all the interacting drugs (.pdb files) from 6 druggable
targets which were found by virtual screening in Drugbank
database. Then we generated the .pdbqt files of these 6 druggable
targets for docking experiments. Blind docking was performed
for the identification of most effective binding site of these drugs.
A grid box parameter for covering the whole protein was set for
all docking runs.
Furtheremore, we have performed ProtParam (http://web.
expasy.org/protparam/) and VaxiJen (http://www.ddg-pharmfac.
net/vaxijen/VaxiJen/VaxiJen.html) server for the identification of
most suitable drug/vaccine target.
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RESULTS AND DISCUSSION
Data Acquisition
A number of potential therapeutic targets in S. flexneri is detected
and categorized through an in silicomethod. The strategy applied
a hierarchy of subtractive analysis where functionally essential
proteins of S. flexneri derived from whole proteome of 13,503
proteins dataset (Drug Target, Data Sheet S1). The number of
subtractive channel was used to select the potential candidates
that could serve either drug or vaccine for therapeutics treatment.
Overall, the strategy composed of stages of data mining,
subtractive channel of analysis and qualitative characterization.
Subtractive Channel of Analysis
Subtraction of Duplicate and Mini Proteins
CD-HIT suite identified the duplicate or paralog proteins from
the proteome. This tool sorted out 4559 proteins as non-duplicate
at sequence identity upto 60% (Drug Target, Data Sheet S2).
Proteins that showed above 60% matching were considered as
duplicates or paralogs in this analysis. We have chosen 60%
similarity as a cut-off to maintain a very stringent selection
criteria for the identification of the most effective therapeutic
targets. Also, we considered to keep one protein from two
identical sequences (>60% similarity) as theymight be similar for
protein domain, motifs, binding site etc. The proteins found from
non-duplicate analysis have various length distribution. Proteins
were excluded from the analysis having length of less than 100
amino acids known as mini proteins (Wang et al., 2008; Kumar
et al., 2010; Barh et al., 2011). Prokaryotic genomes contain a
high level of mini proteins which have key role in numerous
biological phenomenon as well as regulatory purposes (Kumar
et al., 2010). These mini proteins were deleted from the non-
duplicate proteins as they are less likely to represent the essential
therapeutics candidate (Drug Target, Data Sheet S3). In addition
to this, the larger amino acid sequence has the probability to be
involved in essential metabolic pathways (Haag et al., 2012).
Subtraction of Orthologs in Gut Flora
A critical step in this study is to identify proteins that are non-
homologous to gut flora proteins for circumventing extreme
lethal effects in host. It is reported that around 1014 (Kärnell
et al., 1995) microorganisms exist in the gastrointestinal tract of a
normal healthy human (Fujimura et al., 2010). As gut microbiota
maintains a symbiotic relationship, it helps in metabolism by
fermenting indigestible food particles along with defense from
colonization of pathogenic bacteria in gut (Rabizadeh and Sears,
2008). If gut flora proteins are spoiled accidentally it may decline
the microbiota which may cause harm to the host. Therefore,
Human gut flora proteins were subjected to analyze for the
assurance of non-similarity with our selected proteins. BLASTp
was employed to recognize the gut homologs with our selected
proteins and gut flora proteins. Eventually, we have identified
2708 gut flora similar proteins (Drug Target, Data Sheet S4 and
Figure 1).
Subtraction of Orthologs in Human proteome
Identification of pathogen specific protein is the main goal of
this analysis. The importance of this step is to reduce unwanted
cross reactivity of the drug and thus to inhibit its binding to the
active sites of the homologous proteins in host (Sarkar et al.,
2012). In in silico drug target identification method, the first
step is considered as the filtration of homologous proteins to
human proteome (Anishetty et al., 2005; Sarkar et al., 2012).
This non-similarity analysis was carried out for the gut flora
non-similarity proteins datasets. BLASTp was used for similarity
search in contrast to whole proteome of H. sapiens (host) with
e-value threshold of 0.0001 (Altschul et al., 1990). Those Proteins
were considered as close homologs that exhibit hits with proteins
of human proteome. From the analysis of 2708 input proteins
1987 homologous proteins were omitted and 721 proteins were
nominated that are non-homologous to human (Drug Target,
Data Sheet S5 and Figure 1).
Identification of Essential Genes in S. flexneri
DEG server was used for the screening the essential genes
of S. flexneri from human proteome non-homologous protein
list with an estimated value of 0.0001. DEG 6.1 is a
storehouse of genes necessary for the survival of an organism.
It comprises 10,618 essential genes from prokaryotic and
eukaryotic organisms. These types of proteins were considered
as essential and it was clearly demonstrated that similar proteins
which are crucial in one organism are likely to be essential in
another. A potential drug target possesses a crucial feature for the
existence of the pathogen and must be an indispensable protein
(Sarkar et al., 2012). The 67 proteins (Drug Target, Data Sheet S6
and Figure 1) out of 721 non-homologous input proteins were
nominated for the consecutive analysis and considered as vital
for the existence of the pathogen as they have homologs with
not more than the given threshold value (Supplementary Table,
S1). Proteins showing no hit against DEG were omitted from the
analysis and regarded as non-essential.
Metabolic Pathway Analysis
The output of this server assists to identify the potential
drug targets by revealing the KEGG pathways as well as KO
(KEGG orthology) assignments. About 53 proteins are involved
in metabolic pathways obtained from the essential proteins
(Drug Target, Data Sheet S7 and Figure 1). These 53 proteins
(Supplementary Table, S2) have the key role in metabolism for
the bacterial survival.
Qualitative Characterization of Metabolic
Pathway Proteins
Unique Pathway Analysis
Besides the identification of metabolic pathway proteins we have
also analyzed the unique metabolic pathway proteins which
answers the disputable question whether the metabolic pathway
proteins are also present or not in host. Here, we have found 11
unique metabolic pathway proteins that are only present in the
bacterial metabolic pathway (Table 1). These unique proteins
were found in the pathways: Purine metabolism, Pyrimidine
metabolism, Fructose and mannose metabolism, Amino
sugar and nucleotide sugar metabolism, Lipopolysaccharide
biosynthesis, Pyruvate metabolism, Propanoate metabolism
Butanoate metabolism, Lysine biosynthesis, Terpenoid
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FIGURE 1 | Schematic representation of whole work.
TABLE 1 | Proteins involved in unique pathways.
SN Accession no. Name of protein KO number (gene name) Pathways
1 NP_839575.1 DNA-directed RNA polymerase subunit alpha K03040 Purine metabolism, Pyrimidine metabolism
2 NP_838872.1 Mannose-specific IIA component K02794(manX) Fructose and mannose metabolism,
Amino sugar, and nucleotide sugar metabolism
3 NP_838706.1 Arabinose-5-phosphate isomerase K06041 Lipopolysaccharide biosynthesis
4 NP_838628.1 Formate C-acetyltransferase K00656 (pflD) Pyruvate metabolism,
Propanoate metabolism Butanoate metabolism
5 NP_835770.1 4-hydroxy-tetrahydrodipicolinate reductase K00215(dapB) Lysine biosynthesis
6 NP_835768.1 4-hydroxy-3-methylbut-2-enyl diphosphate reductase K03527 (ispH, lytB) Terpenoid backbone biosynthesis
7 AAP19547.1 PTS system, ascorbate-specific IIC component K03475 Phosphotransferase system (PTS)
8 EFS15406.1 penicillin-binding protein 1C K05367 (pbpC) Peptidoglycan biosynthesis
9 EFS14577.1 Flagellar FliJ protein K02413 (fliJ) Flagellar assembly
10 EFS13661.1 Arginine N-succinyltransferase K00673 (astA) Arginine and proline metabolism
11 EFS12253.1 RNA polymerase nonessential primary-like sigma factor K03087 Bacterial pathogenic cycle
backbone biosynthesis, Phosphotransferase system (PTS),
Peptidoglycan biosynthesis, Flagellar assembly, Arginine and
proline metabolism and bacterial pathogenic cycle.
Subcellular Localization
Proteins can be found in five possible subcellular locations,
specifically, cytoplasm, periplasm, plasma membrane, outer
membrane, and extracellular. The importance of the localization
study is to depict the protein as drug or vaccine target. Surface
membrane proteins and cytoplasmic proteins can be used as
vaccine and drug targets respectively (Barh et al., 2011). Protein
databases like UniProt contain information about subcellular
location of some proteins. PSORTb 3.0.2 (Yu et al., 2010),
CELLO 2.0 (Yu et al., 2006), SignalIP (Petersen et al., 2011), and
Phobius (Käll et al., 2007) tools were utilized for the prediction of
subcellular localization.
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Therefore, we have analyzed the essential human non-
homologous metabolic pathway proteins (53) for the prediction
of their subcellular localization. From these analysis we have
found 29 targets as cytoplasmic, 14 targets as inner membrane,
6 targets as periplasmic, 3 targets as outer membrane and only 1
target as extracellular (Table 2).
Broadspectrum Analysis
The progress of drug resistance can be reduced greatly by such
types of broadspectrum and pathogen specific targets analysis
(Raman et al., 2008). In this study, list of pathogenic bacteria
described in literature was well-thought out (Griffith et al., 2007;
Raman et al., 2008; Shenai et al., 2009). It is theorized from
the similarity analysis in contrast to each of the pathogen that
close homologs existing in more number of pathogens are more
expected to be a “promising broad spectrum target” (Raman et al.,
2008). Therefore, we have also analyzed broadspectrum targets
by comparing the sequences analysis between the 240 pathogens
shigella species as well as other clinically important bacterial
pathogens with the selected 53 essential metabolic proteins (Drug
Target, Data Sheet S7). This was done by the BLASTp analysis.
About 25 targets were found to have close identity with less than
10 bacterial pathogens, 10 targets in less than 20 bacteria, 8 targets
in less than 30, 7 less than 40 bacteria, and 3 in less than 50
bacterial pathogens (Table 3). From these results, it is concluded
that these 3 (NP_836465.1, NP_836278.1 and NP_835876.1)
or 7 (NP_837443.1, NP_837438.1, NP_836948.1, NP_836937.1,
NP_836681.1, NP_836675.1 and NP_836672.1) targets are the
exclusive proteins of Shigella.
Interactome Analysis
After data mining, finally identified protein data analyzed and
depicted a PPI network which is shown in (Figure 2). The
networking was established by STRING analysis. In STRING, one
protein is interacted with a number of proteins and showed the
strength of interaction as score. The interacting score depends
on Neighborhood in the genome, Gene fusions, Co-occurrence
across genomes, Co-Expression, Association in curated databases
and text mining (Jensen et al., 2009). Protein network contains
high confidence interactors with score more than or equal to
0.700. Based on the variation in the critical network parameter
values the potentiality of the targets was determined. In the
bacterial metabolic system, the significance of the query protein
was figured out from the number of interacting proteins (nodes)
and interactions (edges) interrupted on its deletion (Kushwaha
and Shakya, 2010). In low confidence score (0.150), all of
the proteins interacted with each other. In highest confidence
score (0.900), 30S ribosomal protein (rpsD), DNA-directed RNA
TABLE 2 | Subcellular localization of drug targets.
Cytoplasmic Inner membrane Periplasmic Outer
membrane
Extracellular
NP_839574.2
NP_839575.1
NP_839064.1
NP_838943.1
NP_838894.1
NP_838872.1
NP_838722.1
NP_838706.1
NP_838628.1
NP_837679.1
NP_837604.1
NP_837597.1
NP_837443.1
NP_836675.1
NP_836672.1
NP_836278.1
NP_835876.1
NP_835770.1
NP_836827.2 (TM;6)
NP_839768.1 (SP),
(TM;1)
NP_839521.1 (TM;12)
NP_839165.1
NP_836948.1 (TM;5)
NP_836937.1 (TM;6)
NP_836465.1 (TM;5)
AAP19547.1 (TM;12)
EFS15406.1
EFS14933.1TM;2)
EFS13325.1
EFS11623.1 (TM;10)
EFS10693.1 (TM;7)
NP_837444.1
NP_839600.1 (SP)
NP_837676.1
NP_836681.1 (SP),
(TM;1)
EFS14577.1
EFS13874.1 (TM;1)
EFS12950.1 (SP)
NP_837438.1
EFS15865.1
EFS15439.1
EFS11306.1
NP_835873.1
NP_835768.1
AAP19293.1
AAP18497.1
AAP16677.1
EFS15144.1
EFS15122.1
EFS13661.1
EFS12253.1
EFS11712.1
EFS10930.1
Here, SP, Signal Peptide; TM, Transmembrane Helices.
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TABLE 3 | Broad spectrum analysis of essential proteins.
Hit pathogenic bacterial protein (240 Pathogenic bacteria)
=>10 =>20 =>30 =>40 =>50
EFS11712.1
EFS11623.1
EFS11306.1
EFS10930.1
EFS10693.1
NP_836827.2
NP_839574.2
NP_837679.1
NP_837676.1
NP_837604.1
NP_837597.1
NP_837444.1
EFS15406.1
EFS15144.1
EFS15122.1
EFS14933.1
EFS14577.1
NP_835770.1
NP_835768.1
AAP19547.1
AAP19293.1
AAP18497.1
AAP16677.1
EFS15865.1
EFS15439.1
NP_837443.1
NP_837438.1
NP_836948.1
NP_836937.1
NP_836681.1
NP_836675.1
NP_836672.1
NP_836465.1
NP_836278.1
NP_835876.1
NP_839768.1
NP_839600.1
NP_839575.1
EFS13874.1
EFS13661.1
EFS13325.1
EFS12950.1
NP_839521.1
NP_839165.1
NP_839064.1
NP_838943.1
NP_838894.1
EFS12253.1
NP_838872.1
NP_838722.1
NP_838706.1
NP_838628.1
NP_837679.1
polymerase subunit alpha (rpoA), RNA polymerase sigma factor
RpoS (RpoS), RNA polymerase-binding transcription factor
(dksA), anti-RNA polymerase sigma 70 factor (rsd), Holliday
junction resolvase (ruvC), Holliday junction DNA helicase
(RuvA), 7,8-dihydropteroate synthase (folP), and 2-amino-4-
hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase
(folK) were shown to interact with each other (Figure 2).
The highest confidence score of interaction found in between
folP and folk which was 0.999. The homologous genes
of those proteins are neighbors of other species and in
addition, putative homologs are reported to interact in other
species.
Functionality Analysis
From the subtractive analysis we have found 6 hypothetical
proteins (Drug Target, Data Sheet S8) which are uncharacterized
proteins from the list of 53 potential targets. Attempts were
made to characterize their function. To predict their function
we have used INTERPROSCAN for the characterization
of their functional domain, Molecular function, and
Biological process (Table 4). But Molecular function and
Biological process also was none predicted in some of the
cases.
Binding Site Analysis
We have selected the best template from the Local
meta-threading-server (LOMETS; Wu and Zhang, 2007)
where more than one threading program showed same template
with higher score (Align Length, Coverage, Z score and
Confidence score; Supplementary Figure S1). After selecting
the template we have prepared the required files for sequence
of interest and template (.ali, .pir, .bin, and python file).
We have run python programming based Modeller software
(Modeller 9.17) for generating the number of models (Webb
and Sali, 2014). Then we have followed the both DOPE (Discrete
Optimized Protein Energy) and GA341 method for selecting
the best model from the number of generated models. As
GA341 is not as good as DOPE at differentiating between
high and low quality model, we have calculated the DOPE
score as it is designed for selecting the best structure from a
collection of models built by MODELLER. We have selected
the best model which shown the lowest DOPE score as it is
reported that lower the DOPE score the better is the model.
Thereafter, we have checked the quality assessment of every
model built by Modeller. We have utilized Ramachandran
Plot (Laskowski et al., 1993), Verify3D (Eisenberg et al.,
1997), and ProSA (Wiederstein and Sippl, 2007) for the model
assessment. All the three tools showed satisfactory results
which are summarized in Supplementary Table, S3, Figures,
S2, S3. Through these results we have confirmed the predicted
model of each hypothetical protein as high-quality. All the
predicted model showed above 90% residues in favorable region
(Supplementary Table, S3). Verify3D and ProSA also confirmed
that the built model are good (Supplementary Figures, S2, S3).
We have also analyzed the binding site and binding site residues
of these hypothetical proteins (Table 5 and Supplementary
Figures, S4–S9).
Druggability Analysis
High binding affinity to the drug like molecule is a major feature
of a “druggable target.” Drug Bank contains 6816 experimental
and FDA-approved drugs, 4326 drug targets and 169 drug
enzymes/carriers. The module estimates the degree of similarity
by using the similarity search option BLASTp program (Mondal
et al., 2015). Presence of targets acts as assign for their druggable
property. In contrast, its absence designates the novelty of
the target and therefore, categorized as “novel target” (Knox
et al., 2011). From the selected 53 targets we have found 6
targets (Drug Target, Data Sheet S9) which showed the similarity
with approved, investigational, and experimental drugs when
the BLASTp search was done against DrugBank database with
cut-off parameters (Table 6). We have observed that target
EFS15406.1 showed the highest similarity with 15 drugs which
could act as inhibitors (both approved and investigational).
The docking energy also revealed that the interacting drugs
have better binding affinity to their respective targets (Table 6).
Therefore, out of 53 therapeutic targets, 47 could be considered
as novel drug targets as the remaining 6 targets showed druggable
properties.
Implications for Drug and Vaccine Development
The 53 targets identified through the current study for vaccine
and drug design against S. flexneri will make inroad for the
development of effective drug(s) and vaccine(s) (Figure 3).
Among the 53 targets 43 were found as novel drug targets
(Figure 3 and Table 6). The development of such therapeutics
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FIGURE 2 | Interactome analysis of the final metabolic proteins.
TABLE 4 | Functionality analysis of Hypothetical proteins.
Name of hypothetical Gene ontology Functional domain Molecular function Biological process
protein
NP_839521.1 GO:0055085 Major facilitator superfamily (4–385) None predicted Transmembrane transport
NP_837604.1 GO:0008237 Metallopeptidase, catalytic domain (44–257) Metallopeptidase activity None predicted
NP_837438.1 None predicted Duplicated Hybrid motif (169–408) None predicted None predicted
NP_836675.1 GO:0048037 NAD(P)-binding domain, coA-binding protein Cofactor binding None predicted
AAP19547.1 GO:0009401 Panther (21–480) None predicted phosphoenolpyruvate-dependent
sugar phosphotransferase system
AAP16677.1 None predicted Putative zinc- or iron-chelating domain
containing protein
None predicted None predicted
might be targeted based on their qualitative characteristics.
S. flexneri specific unique metabolic pathway might be a target
for drug development (Table 1). Drug and vaccine development
might also consider cellular location of the targets: Bacterial
surface appears to be important for the immunogenicity
and surface proteins are more accessible for vaccination.
Therefore, four (4) surface proteins NP_837438.1, EFS15865.1,
EFS15439.1, and EFS11306.1 might be targeted for the vaccine
design.
However, after identification of this vaccine targets we
have analyzed their probable antigen and allergenecity
assessment. And we have found NP_837438.1 could be an
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TABLE 5 | Predicted Binding site for hypothetical proteins and their interacting residues.
Hypothetical CscoreLB PDB Hit TM-score RMSDa IDENa Cov. BS-score Lig. Name Predicted binding site residues
Protein
NP_839521.1 0.01 3mk7D 0.335 7.03 0.035 0.628 0.84 CA 64, 66, 71, 115
0.01 2z1qA 0.386 5.90 0.086 0.575 0.62 FAD 34, 37, 38, 45, 94
0.01 1n38A 0.355 6.67 0.037 0.575 0.73 CH1 277, 278, 309, 312, 313, 314, 375
0.01 2fonB 0.386 5.96 0.084 0.567 0.62 FAD 16, 77, 78, 118, 120, 123
NP_837604.1 0.74 3khiA 0.801 0.18 0.807 0.802 1.58 ZN 124, 161, 165, 224
0.01 3kllA 0.428 6.35 0.054 0.741 0.88 MAL 217, 226, 227, 228, 229
NP_837438.1 0.24 2gu1A 0.721 0.56 0.417 0.725 1.48 ZN 314, 318, 395
0.01 1fiqA 0.143 5.82 0.032 0.207 0.87 FES 345, 346, 363, 384, 385, 386, 387, 392
0.01 2ckjC 0.329 6.76 0.048 0.523 0.83 FES 345, 346, 363, 384, 386, 387, 389, 392
0.01 2ckjA 0.330 6.76 0.048 0.523 0.88 FES 330, 331, 332, 334, 350, 351, 358, 359
0.01 3eubS 0.160 5.78 0.060 0.232 0.91 FES 331, 332, 333, 352, 353, 356, 357
NP_836675.1 0.45 3q9uA 0.692 2.46 0.409 0.826 1.38 COA 37, 38, 40, 42, 45, 46, 64, 65, 66, 67, 68, 96,
97, 100, 104, 119, 120, 143, 145, 146
0.03 1pgqA 0.603 3.22 0.115 0.774 0.93 2AM 63, 64, 65, 94, 95, 104, 108
AAP19547.1 0.01 3eubS 0.163 4.76 0.055 0.211 0.84 FES 352, 353, 377, 378, 379, 382, 384
0.01 2ckjC 0.330 7.93 0.031 0.579 0.86 FES 384, 386, 387, 390, 401, 402, 403, 404
0.01 2ckjB 0.314 7.20 0.039 0.504 0.83 FES 225, 387, 389, 392, 394, 399
0.01 2ckjA 0.324 7.81 0.028 0.558 0.86 FES 41, 42, 43, 47, 65, 66, 67, 68
AAP16677.1 0.57 3o7bA 0.646 3.48 0.145 0.903 0.90 SAH 64, 65, 66, 83, 84, 86, 98, 111, 112, 113, 114,
115, 116, 118, 121
Here, CscoreLB (Confidence score of predicted binding site) predicts a reliable ligand-binding site ranging in between [0 and 1]. BS-score measures between template binding site
and predicted binding site. BS-score >1 reflects a significant binding site between the predicted and template. TM-score measures the global structural similarity between query
and template protein. RMSDa ensures the structurally aligned by TM-align. IDENa measures the percentage of sequence identity in the structurally aligned region. Cov. embodies the
coverage of global structural alignment.
ideal target for the epitope based peptide vaccine as it showed
probable antigenecity and non-allergenecity (Supplementary
Table, S4).
Membrane proteins are the gateways to the cell: many
nutrients, ions, waste products, and even DNA and proteins
enter and leave cells via proteins which are tightly controlled,
maintaining the integrity of the cell. Drugs often target
membrane proteins; therefore, understanding their molecular
structure helps us design better drugs to cure diseases. We have
found 14 targets identified through this analysis can be suitable
for drug design (Table 2).
Besides, Membrane localized proteins are sometimes difficult
to purify and assay (Duffield et al., 2010) and therefore,
cytoplasmic proteins are more favorable as drug targets. We
have found 35 targets which might be suitable for drug design
(Table 2).
A promising drug target should have better physicochemical
properties such as increased hydrophobicities, in vivo half-
lives, propensity for being membrane bound and the
stability of protein (Bull and Doig, 2015). Our analysis
also revealed 14 targets (NP_836827.2, NP_839521.1,
NP_837679.1, NP_837676.1, NP_837444.1, NP_837443.1,
NP_836948.1, NP_836675.1, NP_835770.1, AAP19547.1,
EFS14933.1, EFS13325.1, EFS11623.1, EFS10693.1) among
the 49 suitable drug targets which showed protein stability,
increased half -life propensity, greater hydrophobicity etc.
(Supplementary Table, S5). We observed 13 targets as novel
candidate where only NP_835770.1 target showed druggable
(Figure 3).
Also, the functions of each identified targets including
hypothetical targets may be exploited for the identification or
design drug/vaccine for effective therapy against S. flexneri. In
the perspectives of broadspectrum analysis we have identified
some targets which might be used as “promising broadspectrum
targets” as they cover the targets more than 40–50 pathogenic
bacteria including S. flexneri. From the 13 novel drug targets we
investigated NP_837443.1 as the most suitable drug candidate
which covers the target similarity of 40 pathogenic bacteria
including Shigella (Figure 3). The identification of the suitable
target(s) is the key device for drug discovery. Our identified
promising target (NP_837443.1) plays an important role in
Holliday junction which exchanges the segments of genetic
information during recombination as well as Helicase activity
for the survival of S. flexneri. For the drug discovery against
this target we need to identify the conserved domain responsible
for Holliday junction. The effective binding site and its active
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TABLE 6 | Druggability properties of metabolic human non-homologous essential proteins.
Protein ID DrugBank ID Drug name Drug group Pharmacological Docking energy Chemical formula
action (Kcal/mol)
NP_835873.1 DB00233 Aminosalicylic Acid Approved Unknown −7.8 C7H7NO3
NP_835770.1 DB04267 Dipicolinic Acid Experimental Unknown −8.1 C7H5NO4
AAP18497.1 DB00259 Sulfanilamide Approved Inhibitor −7.1 C6H8N2O2S
DB00264 Sulfisoxazole Approved, Vet_approved Inhibitor −7.5 C11H13N3O3S
DB00576 Sulfamethizole Approved, Vet_approved Inhibitor −8.7 C9H10N4O2S2
DB00634 Sulfacetamide Approved Inhibitor −6.9 C8H10N2O3S
DB01015 Sulfamethoxazole Approved Inhibitor −8.0 C10H11N3O3S
DB01298 Sulfacytine Approved Inhibitor −7.8 C12H14N4O3S
DB01581 Sulfamerazine Approved, Vet_approved Inhibitor −8.8 C11H12N4O2S
DB01582 Sulfamethazine Approved, Vet_approved Inhibitor −6.5 C12H14N4O2S
DB06729 Sulfaphenazole Approved Inhibitor −7.0 C15H14N4O2S
EFS15406.1 DB00274 Cefmetazole Approved Inhibitor −8.3 C15H17N7O5S3
DB00303 Ertapenem Approved, Investigational Inhibitor −8.4 C22H25N3O7S
DB00430 Cefpiramide Approved Inhibitor −6.9 C25H24N8O7S2
DB00438 Ceftazidime Approved Inhibitor −8.0 C22H22N6O7S2
DB01327 Cefazolin Approved Inhibitor −7.7 C14H14N8O4S3
DB01328 Cefonicid Approved Inhibitor −6.8 C18H18N6O8S3
DB01329 Cefoperazone Approved Inhibitor −7.8 C25H27N9O8S
DB01331 Cefoxitin Approved Inhibitor −7.9 C16H17N3O7S2
DB01332 Ceftizoxime Approved Inhibitor −6.7 C13H13N5O5S2
DB01333 Cefradine Approved Inhibitor −7.2 C16H19N3O4S
DB01414 Cefacetrile Approved Inhibitor −7.0 C13H13N3O6S
DB01415 Ceftibuten Approved Inhibitor −6.1 C15H14N4O6S
DB01598 Imipenem Approved Inhibitor −6.6 C12H17N3O4S
DB04570 Latamoxef Approved Inhibitor −7.9 C20H20N6O9S
DB06211 Doripenem Approved, Investigational Antagonist, Inhibitor −6.8 C15H24N4O6S
EFS13874.1 DB02767 3-Hydroxy-Myristic Acid Experimental Unknown −7.2 C14H28O3
DB04147 Lauryl Dimethylamine-N-Oxide Experimental Unknown −6.9 C14H31NO
DB08231 MYRISTIC ACID Experimental Unknown −7.5 C14H28O
EFS11712.1 DB01862 Isopropyl beta-D-
thiogalactopyranoside
Experimental Unknown −6.0 C9H18O5S
DB08297 ORTHONITROPHENYL-BETA-
D-FUCOPYRANOSIDE
Experimental Unknown −7.2 C12H15NO7
residues of this domain should also be identified for the drug
design. Finally, drug-target binding affinity of this binding site,
ADMET (Absorption, Distribution, Metabolism, and Excretion),
QSAR (Quantitative Structural Activity Relationship), and
toxicity measurement will lead the way to inhibit the function
of this target protein. Further, animal model experiment
must be needed to confirm the drug efficacy against this
target.
As the selection of effective therapeutics targets are the
crucial things for the vaccine and drug design (Hasan et al.,
2015; Khan et al., 2015; Oany et al., 2015; Hossain et al.,
2016a,b; Hossain and Oany, 2016d) as well as for the building of
networking (protein-protein interaction; Hossain et al., 2016c),
our subtractive strategy will have a great impact in therapeutics
discovery against S. flexneri.
CONCLUSION
Subtractive channel analysis in proteome of S. flexneri 2a
str. 2445T suggest 53 drug targets and further with their
qualitative characterization stage explicates unique metabolic
pathways, localization of targets, broadspectrum, functionality,
interactome, and druggable properties. This studymight facilitate
the development of drug and vaccines against S. flexneri as well as
come to be handy in clinical interest with identification of drug
candidates against other pathogens.
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FIGURE 3 | Prioritization of total therapeutic proteins (53). TTT, Total therapeutic targets; TVT, Total vaccine target; NDT, Novel drug targets; HP, Hypothetical
proteins; UPP, Unique pathway proteins; OM, Outer membrane proteins; EC, Extracellular proteins; CP, Cytoplasmic proteins; TP, Transmembrane proteins; BS,
Broadspectrum. Here, cytoplasmic proteins, 4 (NP_837679.1, NP_837676.1, NP_837443.1, NP_836675.1,) and Transmembrane proteins, 9 (NP_836827.2,
NP_839521.1, NP_837444.1, NP_836948.1, AAP19547.1, EFS14933.1, EFS13325.1, EFS11623.1, EFS10693.1).
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